clinical trial · NCT05421663
A Study of JNJ-90014496 in Participants With B-Cell Non-Hodgkin Lymphoma
Janssen Research & Development, LLC·phase2·active not recruiting·n = 166
Lymphoma, Non-HodgkinLymphoma, B-CellLymphoma, Large B-Cell, DiffusePrizloncabtagene autoleucel (Prizlo-Cel)
brief summary
This is a Phase 1b/2, multicenter, open-label, study of prizloncabtagene autoleucel (prizlo-cel), an autologous dual targeting chimeric antigen receptor (CAR) T-cell therapy targeting both cluster of differentiation (CD) CD20 and CD19, for the treatment of adult participants with relapsed or refractory (r/r) B-Cell non-Hodgkin lymphoma (B-NHL) or frontline high-risk diffuse large B-cell lymphoma (DLBCL).
started
Aug 12, 2022
primary completion
Dec 29, 2028
completion
Jul 30, 2041
last updated
Jul 6, 2026
official title
A Phase 1b/2, Multicenter, Open-label, Study of JNJ-90014496, an Autologous CD19/CD20 Bi-specific CAR-T Cell Therapy in Adult Participants With B-cell Non-Hodgkin Lymphoma
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol